Deciphera Pharmaceuticals Inc Revenue Growth Rates (DCPH), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Industry, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
Deciphera Pharmaceuticals Inc   (NASDAQ: DCPH)
 

DCPH's Revenue Growth by Quarter and Year

Deciphera Pharmaceuticals Inc 's Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

DCPH Revenue (in millions $) FY 2024 FY 2023 FY 2022 FY 2021
4th Quarter December -
3rd Quarter September -
2nd Quarter June -
1st Quarter March 45.00
FY 45.00

DCPHs Annual Revenue
Deciphera Pharmaceuticals Inc 's Revenue in the fiscal year 2023 $ 163.36 millions
Deciphera Pharmaceuticals Inc 's Revenue in the fiscal year 2022 $ 134.04 millions
Deciphera Pharmaceuticals Inc 's Revenue in the fiscal year 2021 $ 96.15 millions
Deciphera Pharmaceuticals Inc 's Revenue in the fiscal year 2020 $ 42.09 millions
Deciphera Pharmaceuticals Inc 's Revenue in the fiscal year 2019 $ 25.00 millions




DCPH Revenue first quarter 2024 Y/Y Growth Comment
Deciphera Pharmaceuticals Inc reported Revenue improvement of 34.53% year on year in the first quarter 2024, to $ 45.00 millions, this is lower than Deciphera Pharmaceuticals Inc 's recent average Revenue surge of 1774.01%.

Looking into first quarter 2024 results within Major Pharmaceutical Preparations industry 69 other companies have achieved higher Revenue growth. While Deciphera Pharmaceuticals Inc ' s Revenue rise of 34.53% ranks overall at the positon no. 445 in the first quarter 2024.


DCPH Revenue ( Y/Y Growth %) 2024
 2023 2022 2021
4th Quarter December - 32.85 % 50.21 % 24.17 %
3rd Quarter September - 20.41 % 54.91 % 50.29 %
2nd Quarter June - 17.88 % 37.84 % 232.44 %
1st Quarter March 34.53 % 14.48 % 16.14 % 41833.33 %
FY   - 21.88 % 39.4 % -

Financial Statements
Deciphera Pharmaceuticals Inc 's first quarter 2024 Revenue $ 45.00 millions DCPH's Income Statement
Deciphera Pharmaceuticals Inc 's first quarter 2023 Revenue $ 33.45 millions Quarterly DCPH's Income Statement


DCPH Revenue (Quarter on Quarter Growth %)

 2024
 2023 2022 2021
4th Quarter December - 11.5 % 1.06 % 4.22 %
3rd Quarter September - 13.08 % 10.71 % -1.48 %
2nd Quarter June - 14.5 % 11.19 % -6.32 %
1st Quarter March -6.82 % -7.98 % 20.74 % 29.09 %
FY (Year on Year)   - 21.88 % 39.4 % -


Back to DCPH Growth rate Comparisons >> Back to DCPH Growth rate Comparisons >>


Revenue first quarter 2024 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #70
Healthcare Sector #132
Overall #445

Revenue Y/Y Growth Statistics
High Average Low
40474.19 % 1774.01 % -100 %
(Mar 31 2021)   (Sep 30 2019)
Revenue first quarter 2024 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #70
Healthcare Sector #132
Overall #445
Revenue Y/Y Growth Statistics
High Average Low
40474.19 % 1774.01 % -100 %
(Mar 31 2021)   (Sep 30 2019)

Revenue by Quarter for the Fiscal Years 2021, 2022, 2023, 2024

Deciphera Pharmaceuticals Inc 's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
11335.48 % 441.03 % -100 %
(Jun 30 2020)  


DCPH's I. Quarter Q/Q Revenue Comment
In the I. Quarter 2024 Deciphera Pharmaceuticals Inc disclosed decline in Revenue from the fourth quarter by -6.82% to $ 45.00 millions, from $ 48.29 millions achived in the previous reporting period.

But that's not important problem, as Deciphera Pharmaceuticals Inc 's Revenue generally seem to plunge in this quarter.

Within Major Pharmaceutical Preparations industry 117 other companies have achieved higher Revenue quarter on quarter growth. While Deciphera Pharmaceuticals Inc 's Revenue growth quarter on quarter, overall rank is 2442.


Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #118
Healthcare Sector #337
Overall #2442
Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #118
Healthcare Sector #337
Overall #2442
Revenue Q/Q Growth Statistics
High Average Low
11335.48 % 441.03 % -100 %
(Jun 30 2020)  


DCPH's I. Quarter Q/Q Revenue Comment
In the I. Quarter 2024 Deciphera Pharmaceuticals Inc disclosed decline in Revenue from the fourth quarter by -6.82% to $ 45.00 millions, from $ 48.29 millions achived in the previous reporting period.

But that's not important problem, as Deciphera Pharmaceuticals Inc 's Revenue generally seem to plunge in this quarter.

Within Major Pharmaceutical Preparations industry 117 other companies have achieved higher Revenue quarter on quarter growth. While Deciphera Pharmaceuticals Inc 's Revenue growth quarter on quarter, overall rank is 2442.


Deciphera Pharmaceuticals Inc 's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Mar 31 2024)		 12 Months Ending
(Dec 31 2023)		 12 Months Ending
(Sep 30 2023)		 12 Months Ending
(Jun 30 2023)		 12 Months Ending
(Mar 31 2023)
Cumulative Revenue 12 Months Ending $ 174.91 $ 163.36 $ 151.41 $ 144.07 $ 138.26
Y / Y Revenue Growth (TTM) 26.51 % 21.87 % 24.22 % 32.01 % 37.96 %
Year on Year Revenue Growth Overall Ranking # 346 # 12 # 34 # 611 # 430
Seqeuential Revenue Change (TTM) 7.07 % 7.89 % 5.09 % 4.2 % 3.15 %
Seq. Revenue Growth (TTM) Overall Ranking # 1728 # 96 # 1226 # 1457 # 1973


Cumulative Revenue growth Comment
Although Deciphera Pharmaceuticals Inc 's Annual Revenue growth year on year were below company's average 33.36% , Revenue announced in the Mar 31 2024 period, show improvement in Revenue trend, to cumulative trailing twelve month growth of 26.51% year on year, from 21.87% in Dec 31 2023.

In the Healthcare sector 114 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 12 to 346.

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 118
Healthcare Sector # 115
Overall # 346

Revenue TTM Y/Y Growth Statistics
High Average Low
128.45 %
 33.36 %
-106.53 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 118
Sector # 317
S&P 500 # 1728
Cumulative Revenue growth Comment
Although Deciphera Pharmaceuticals Inc 's Annual Revenue growth year on year were below company's average 33.36% , Revenue announced in the Mar 31 2024 period, show improvement in Revenue trend, to cumulative trailing twelve month growth of 26.51% year on year, from 21.87% in Dec 31 2023.

In the Healthcare sector 114 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 12 to 346.


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 118
Healthcare Sector # 115
Overall # 346

Revenue TTM Y/Y Growth Statistics
High Average Low
128.45 %
33.36 %
-106.53 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 118
Sector # 317
S&P 500 # 1728




Other Revenue Growth
Major Pharmaceutical Preparations Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
DCPH's Revenue Growth Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue decline for the quarter ending Mar 31 2024 within Healthcare SectorY/Y Change %Revenue for the quarter ending Mar 31 2024
Uniqure N v 59.34%$ 59.343 millions
Atrium Therapeutics Inc 58.67%$ 58.665 millions
Alnylam Pharmaceuticals Inc 54.82%$ 54.823 millions
Kyntra Bio Inc 54.59%$ 54.592 millions
Sunshine Biopharma Inc 54.09%$ 54.086 millions
Sanuwave Health Inc 53.27%$ 53.272 millions
Xtant Medical Holdings Inc 52.16%$ 52.160 millions
Natera Inc 52.11%$ 52.112 millions
Eyepoint Inc 52.08%$ 52.076 millions
Intra cellular Therapies Inc 52.00%$ 52.001 millions
Prosomnus Inc 47.63%$ 47.632 millions
Aurinia Pharmaceuticals Inc 46.19%$ 46.191 millions
Agios Pharmaceuticals Inc 46.00%$ 45.998 millions
Hims and Hers Health Inc 45.78%$ 45.775 millions
Viskase Holdings inc 44.74%$ 44.743 millions
Genedx Holdings Corp 44.67%$ 44.674 millions
Astrotech Corp42.86%$ 42.857 millions
Adma Biologics Inc 42.51%$ 42.511 millions
Evolus Inc 42.21%$ 42.214 millions
Agilon Health Inc 41.21%$ 41.210 millions
Clearpoint Neuro Inc 40.60%$ 40.604 millions
Orthopediatrics Corp39.84%$ 39.844 millions
Theravance Biopharma inc 39.22%$ 39.224 millions
Corcept Therapeutics Inc38.95%$ 38.952 millions
Zai Lab Limited38.78%$ 38.779 millions
Qhslab Inc 38.49%$ 38.489 millions
Tela Bio Inc 38.28%$ 38.277 millions
Shockwave Medical Inc 35.72%$ 35.720 millions
Biocryst Pharmaceuticals Inc 34.87%$ 34.870 millions
Deciphera Pharmaceuticals Inc 34.55%$ 34.546 millions


About Deciphera Pharmaceuticals Inc Revenue Growth Rates (DCPH), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: the company’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.